Clinical development of OX390 (ATIPAMEZOLE) as an ?2 agonist reversal agent for human use to counteract the sedative effects of xylazine, medetomidine, and other ?2 agonists
Active Definitive Contract Awarded Last action
- Contract number
- 75A50125C00010
- Awardee
-
Orexo US Inc. UEI MN1MPMBCVVD5 Part of Orexo AB
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $11,450,712
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Solicitation · BAA23100SOL00004 · Posted Sep 26, 2023
- Contract value 21% obligated
-
- $11,450,712.00 Current, with exercised options
- $53,897,251.50 Potential, with all options
- Completion date 18% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Sharing
- Place of performance
- Morristown, NJ 07960, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $2,999,997 | |
| Original award | $8,450,715 |
About this award
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Orexo US Inc. on September 24, 2025, for clinical development of OX390 (atipamezole) as an α2 agonist reversal agent to counteract sedative effects of xylazine, medetomidine, and other α2 agonists, with a ceiling value of $53.9 million under cost-sharing pricing.
The award adds supplemental funding to and extends the period of performance for Clinical 0001 and 0002 through December 31, 2027, updates key personnel and statements of work, and modifies FAR and HHSAR clauses. The ultimate completion date is February 4, 2032. Place of performance is Morristown, NJ.
The contract originated from a BARDA solicitation (posted September 26, 2023) that seeks advanced research and development proposals for medical countermeasures against chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases. The solicitation encompasses twelve areas of interest, with Technology Readiness Level requirements generally ranging from TRL 4 to TRL 6. Evaluation emphasizes technical merit and importance to agency programs, with assessment across program relevance, scientific and technical merit, offeror capabilities, cost realism, and past performance. All work is performed in the United States with preference for U.S.-based manufacturing and technologies rapidly adaptable to emerging threats.
Quick answers
Who was awarded contract 75A50125C00010?
75A50125C00010 was awarded to Orexo US Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 24, 2025.
How much is contract 75A50125C00010 worth?
The government has obligated $11,450,712 on 75A50125C00010. Its potential value, with all options, is $53,897,252.
Was contract 75A50125C00010 competed?
The extent of competition for 75A50125C00010 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award